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Abbreviations 
Ct: drug concentration at the same time point; 
D-plaster: diclofenac epolamine-loaded plaster; 
ESI: electron spray ionization; 
GMR: geometric Mean Ratio; 
HVDP: highly variable drugs or drug products; 
J: maximal permeation flux; 
Jtot: permeation flux calculated on the basis of real-life application area; 
L: lower limit of acceptability interval; 
MRM: multiple reaction monitoring; 
N-patch: nitroglycerine-loaded patch; 
P-patch: propranolol-loaded patch; 
Qt: permeated amount at the time t; 
R: electrical resistance; 
U: upper limit of acceptability interval; 
V: volume of the Franz cell. 
  
3 
 
1 Introduction 
Transdermal patches and medicated plasters are well-known prolonged release dosage forms designed to 
guarantee efficacious drug concentrations to the systemic circulation or in the tissues beneath the application 
site, respectively. The interest in these adhesive dosage forms resides in the possibility to prolong the drug 
release over a period ranging from 12 hours to 7 days and to pre-determine the administered dose.  
To achieve these goals, the adhesion to the skin surface and the ability to release the loaded drug through the 
stratum corneum over the required period of time are key requirements in the design of these formulations. 
Both of these aspects should be carefully evaluated in the pharmaceutical development taking into 
consideration that all the formulation variables can influence both the drug release/permeation and the 
adhesion properties.  
The design of the in vitro skin penetration experiments, the selection of the diffusion cell and the relative 
operative conditions, as well as the biological membrane, are crucial. The most widely used diffusion cells 
are based on the design proposed by Franz even if some modifications have been introduced (Ng et al., 
2010). The diffusion surface and the volume of the receiver chamber of these cells have to be chosen in order 
to guarantee detectable concentrations of the permeant in the receiver medium. Moreover, the agitation 
system should be validated (Ng et al., 2010) to assure a uniform concentration of the permeant in the receiver 
medium, whose composition has to be suitable to guarantee the sink conditions and avoid any significant 
alteration of the barrier properties of the biological membrane. The last aspect is obviously the most critical 
variable. Usually, the human skin or the isolated human epidermis are used even if the porcine skin is often 
used as a surrogate (Campani et al., 2016; Heylings et al., 2018). Regardless of the source of the biological 
membranes used in the permeation study, the demonstration of their integrity has to be demonstrated and, in 
consideration that a compendium method is not available, the suitability of the adopted method has to be 
accurately studied (Davies et al., 2015). Moreover, the whole procedure should be periodically controlled 
using standard molecules (i.e., caffeine benzoic acid or testosterone) as suggested by the OECD(OECD, 
2004). It should be also kept in mind that the suitability of the diffusion cell system for the determination of 
the skin permeation of a drug has to be accomplished by an appropriate statistical approach which allows to 
discriminate the similarity or dissimilarity of two formulations containing the same active pharmaceutical 
ingredient.  
Recently, the EMA introduced a new guideline “on the quality of transdermal patches” which reports the 
critical attributes of a transdermal patch and establishes the requirements necessary to assess its quality 
(EMA, 2014). The in vitro permeation data are particularly emphasized since they have a key role not only in 
the development and optimization of the formulation but are also supportive of the stability data. Finally, 
when the in vitro permeation assay is discriminative of the critical variables, it results helpful in the 
management of the variations that can occur during the cycle life of the drug product. 
Interestingly, the guideline reports the general concept that in vitro skin permeation studies are a valuable 
measure of the patch biopharmaceutical performances since they allow to estimate the thermodynamic 
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activity of the drug in the adhesive matrix even if the “in vitro permeation studies are not expected to 
correlate with in vivo release”. Indeed, the thermodynamic activity of the drug is the main driving force in 
the partition process occurring between the patch and the stratum corneum that is the first step for the drug 
absorption. Hence the in vitro skin permeability studies can be considered as a surrogate of the in vivo 
studies and the need to perform bioequivalence studies might be waived in certain cases (Cilurzo et al., 
2015a). Indeed, although the in vitro permeation data do not fit always the expected one to one relation with 
the in vivo data (Franz et al., 2009), a certain proportionality between the in vitro and in vivo fluxes is 
maintained, therefore a direct in vitro-in vivo correlation of the biopharmaceutical performances has been 
postulated and well established, either for local (Minghetti et al., 2000) and systemic administration (Rohr et 
al., 1998). 
The European Guideline on the quality of transdermal patches proposes the comparison of the 
experimentally determined fluxes upon a null hypothesis of non-equivalence. According to the guideline for 
the assessment of in vivo bioequivalence, the 90% confidence interval for the ratio of the two products 
should be determined and comprised within the ratio of 0.8 to 1.25 to support a claim of equivalence, unless 
justified. However, unlike the in vivo bioequivalence study, the guideline suggests the number of replicas 
without considering that the variability of the permeation process may be strongly dependent on the 
characteristics of the permeant (Farahmand and Maibach, 2009). Nevertheless, it is well-known that the 
diffusion process through the skin is determined by both the physiological variability of the excised 
biological sample and the physicochemical properties of the permeant. As widely demonstrated in the 
literature, the permeation pattern of hydrophilic drug substances is more variable than that of hydrophobic 
ones. For example, Akomeah and co-workers demonstrated that the intra- and inter-skin donor variability of 
caffeine resulted higher than the variability of methyl and butylparaben (Akomeah et al, 2007). Thus, unlike 
the in vivo bioequivalence studies, the establishment of the number of replicas for the in vitro skin 
permeation studies could be critical taking also in consideration that these experiments have to be considered 
as parallel experiments. Indeed, once exposed to the formulation and the acceptor medium, the epidermis 
sample cannot be re-used since the features of the biological membrane at the end of experiment could be 
modified and a certain amount of drug would have been retained in the tissue.  
Basing on these considerations, this work aimed to evaluate the effect of the variability of the permeant in 
the diffusion process through the epidermis, to provide suggestions helpful to rationalize the design of 
bioequivalence assessment experiments of two transdermal patches. On the basis of the literature data, 
propranolol and diclofenac epolamine were selected as model drugs having a low and a high skin permeation 
variability, respectively. Indeed, the propranolol exhibits an intra-subject variability lower than 30% (Cilurzo 
et al., 2014a; Casiraghi et al., 2016), whilst the diclofenac salts have generally a larger variability (Cilurzo et 
al., 2015b; Dehghanyar et al., 2015). Thus, in the design of the experiments, we decided to follow the 
European Guideline indication (6 replicas) in the case of propranolol patches and to increase the number of 
replicas up to 20 in the case of diclofenac plasters. Moreover, since transdermal patches can claim the same 
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in vivo performances but different surface, two commercially available patches of nitroglycerine having 
different strength and patch surface were also tested in terms of in vitro performances. In this case, the 
number of replicas was reduced to that proposed by OECD guideline, because of the low variability of the 
skin permeation behavior of nitroglycerine (OECD, 2004). 
 
2 Materials and methods 
2.1 Materials 
Propranolol-loaded patches: Propranolol was obtained by SIMS (I); Eudragit NE 40D was purchased by 
Evonik (D); N-methyl pyrrolidone was obtained by Sigma–Aldrich (US) and DURO-TAK 87-608A 
(Henkel); backing layers: polyethylene membrane and silicon polyester release liner were gently provided by 
Bouty (I). 
Propranolol-loaded patches (1.49 mg/cm
2
) were prepared according to Cilurzo et al. (Cilurzo et al., 2014a) 
and have the composition reported in the previous paper: in particular, P-Patch no. 1 corresponds to the 
formulation 7 and P-Patch no. 2 to the formulation 11.  
Diclofenac epolamine-loaded plasters: D-plaster 1 (Flector®; 1.29 mg/cm
2
, Bayer S.p.A, I) was purchased in 
a Community pharmacy, whereas D-plaster 2 was provided by MIAT S.p.A. maintaining the same 
qualitative composition of D-plaster 1.  
Nitroglycerine-loaded patches: the nitroglycerine patches used in the study have the following specifications. 
N-patch 1: drug content 37.4 mg; patch surface 18 cm
2
 (Deponit 10 mg/24h, UCB Pharma GmbH, D); N-
patch 2: drug content 44.8 mg; patch surface 14 cm
2
 (Triniplas 10 mg/24h Novartis S.p.A, I). Both products 
were purchased in a Community pharmacy. 
2.2 In vitro skin permeation studies 
The Franz diffusion cells are used to investigate the kinetics of drug release rate in vitro. This cell comprises 
two compartments, one containing the active component (donor vehicle) and the other containing a receptor 
solution, separated by a slice of human epidermis. The vertical cells used in the actual set of experiments had 
a wider column than the original Franz-type diffusion cell, and the bowl shape was removed. They had a 
diffusion area of 0.636 cm
2
 and a 3.0 mL (approx.) receptor compartment. The receptor volume of each cell 
was equipped with a magnetic stirrer and individually calibrated.  
 
2.2.1 Human epidermis sample preparation  
The skin samples were obtained from surgical abdominal reduction (Eurasian female, 30-50 years old) with 
the informed consent of the patient.  
Skin samples were prepared following an internal standard procedure (Cilurzo et al., 2014b). The full 
thickness skin was sealed in evacuated plastic bags and frozen at -20°C within 6 h after removal. After 
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removing the subcutaneous fatty tissue, the skin was kept frozen at -20°C (Labor 2T 500 ECT-F Touch, 
Fiocchetti, Italy) until use.  
Prior to experiments, the skin was thawed at room temperature, and the excess of fat was carefully removed. 
The skin sections were cut into squares of about 5 cm
2
 and, after immersing the skin in water at 60°C for 1 
min, the epidermis was gently separated from the remaining tissue by forceps.  
The integrity of each human epidermis samples was assessed measuring their electrical resistance (voltage: 
100 mV, frequency: 100 Hz; Agilent 4263B LCR Meter, Microlease, Italy). The specimen was used in the 
permeation experiment if the values were higher than 20 kΩcm2. This acceptability criterion was assessed on 
a series of skin permeation studies performed by using caffeine, benzoic acid and sodium dodecyl sulphate as 
model compounds (Musazzi, 2018). 
 
2.2.2 Mounting the Franz cell  
A 2.0 cm
2
 circular sample, obtained from medicated plaster by a precision die cutter, was gently applied to 
the epidermis specimen. Then, the assembly was mounted on the receiver compartment of the Franz 
diffusion cell filled with saline solution, containing sodium azide (100 μg/mL), as a preservative and 
maintained at 34±1°C, so that the skin surface temperature was 32±1°C. Special care was taken to avoid air 
bubbles between the medium and the epidermis in the receptor compartment that was continuously stirred 
with a small magnetic bar at 1800 rpm to assure a uniform concentration of the permeant. The upper and 
lower parts of the Franz cell were sealed with Teflon (VWR International, I) and Parafilm® (Pechiney 
Plastic Packaging Company, USA) and fastened together by means of a clamp.  
At predetermined times (1, 2, 4, 8, 24 h), 200 μL samples were withdrawn from the receiver compartment 
and replaced with fresh receiver medium. Sink conditions were maintained throughout the experiments.  
Samples were analyzed by HPLC according to the methods described below. 
2.2.3 Data analyses  
The following parameters were calculated starting from the concentrations withdrawn from the receiver 
compartment of the Franz cell: 
a) the cumulative amount permeated through the cell per unit of area was calculated according to the 
equation: 
   
  
   
  
   
  
  
             
  
  
               
  
  
           
         
       (1) 
where Qt is the permeated amount at the time t, Ct is the drug concentration at the same time point, V is the 
volume of the Franz cell, 0.2 mL is the volume withdrawn from the receiver compartment at each time point 
and 0.636 cm
2
 is the surface area of the Franz cell.  
The Qt values were plotted as a function of time. Such plot should yield a straight line; 
b) the maximum flux, J (
    
   
 , of the drug permeated through the skin was calculated as the slope of the 
linear portion of the cumulative curve. 
7 
 
 
2.3 HPLC analyses 
2.3.1 Propranolol 
The quantification of propranolol permeated amount was performed using the analytical method described 
by Cilurzo and co-workers (Cilurzo et al., 2014). Briefly, an Agilent 1100 HPLC system equipped with an 
1100 autosampler, an 1100 quaternary pump with degasser, an 1100 thermostated column compartment, and 
1100 diode array detector was used (Agilent, US). A reverse-phase column was used as the stationary phase 
(Bondclone C18, 10 mm, 3.9x300 mm, Phenomenex, US) and a combination of acetonitrile with 0.2% 
phosphoric acid at the ratio of 30:70 at 25 °C was used as the mobile phase. The flow rate was set at 1.0 
mL/min. The injection volume was 20 μL. The retention time of PR was 7.1 min. The drug concentration 
was determined from three standard calibration curves in the range 0.005–5, 1–40 and 10–200 µg/mL. The 
limit of quantification was determined at 0.004 µg/mL. 
2.3.2 Diclofenac epolamine 
Experiments were performed on an LC-320 with an electron spray ionization (ESI) source and a 320-MS 
triple quadrupole mass spectrometer, equipped with two 212 LC chromatographic pumps and a 410-tray 
cooled autosampler (Varian, US). The system was managed by MS Workstation software Version6.9.1 
(Varian, US). The ESI-triple quadrupole mass spectrometer was set to perform collision-induced dissociation 
experiments in positive ionization mode, using argon as a collision gas. Particularly, multiple reaction 
monitoring (MRM) experiments were conducted by the continuous injection at a rate of 20 µL/min of the 
standards of interest (2 µg/mL) into the mass spectrometer set in positive ionization mode, in methanol 
solutions. In order to enhance ion formation and to improve conductivity, the ESI parameters and the 
chromatographic conditions were set up according to preliminary studies. The method was optimized for the 
research of the ions of interest, for example, the specific MRM transitions of each standard. In detail, once 
recognized the molecular ion of each standard (M + H+), MRM experiments were performed to study the 
characteristic fragmentation pattern of the analytes. ESI source settings and mass spectrometer parameters 
used for compound identification were Needle Voltage: +5000V; Shield Voltage: +600V; Nebulizing Gas 
(N2) Pressure: 30.00 psi; Drying Gas (N2) Pressure: 30.00 psi; Drying Gas (N2) Temperature: 250 °C; Q0 
Offset: +3.0V;L4 Offset: +2.000V; Housing Temperature: 50°C; CID Gas (Ar); Pressure: 2.00 mTorr; 
Electron multiplier: 1750.0V; Scan time: 0.9 sec; Dwell time: 0.1 sec. 
Chromatographic column: Raptor Biphenyl Restek 100 x 2.1 mm i.d. particle size 2.7 µm; (Restek, US); pre-
column: Security Guard Cartridges Raptor Biphenyl (Restek, US); column temperature: 40 °C; manifold 
temperature: 42 °C; housing temperature: 50 °C; flow rate: 200.0 μL/min; injection volume: 20 μL; injection 
mode: partial loopfill; solvent A: formate buffer 3mM + 0.1% formic acid; Solvent B: Methanol; mobile 
phase: solvents were filtered under vacuum on 0.45 μm membrane filters and degassed by immersion in 
ultrasonic bath for 15 minutes before column conditioning; linear gradients: 0.0-1.0 min, 60% B; 2.0-6.0 
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min, 90% B; 7.0-9.0 min 60%. Retention times: diclofenac 5.0±0.2 min; IS (Indomethacin) 5.9±0.2 min. The 
linearity of Diclofenac base was in 20 to 2000 ng/mL range. 
2.3.3 Nitroglycerine 
The quantification of nitroglycerine in the receiver medium was determined using an Agilent 1100 HPLC 
system equipped with an 1100 autosampler, an 1100 quaternary pump with degasser, an 1100 thermostated 
column compartment, and 1100 diode array detector was used at 220 nm (Agilent, US). A reverse-phase 
column C18 was used as the stationary phase (Spherisorb ODS2, 5 μm, Shandon HPLC, UK). A 
combination of methanol, water and tetrahydrofuran (54:43:3) was used as the mobile phase. The flow rate 
was set at 1.0 mL/min. The injection volume was 10 μL. The drug concentration was determined from three 
standard calibration curves in the range 0.001–0.1 mg/mL.  
2.4 Statistical analyses 
The possible outliners within each series were checked by Dixon’s Q test and eventually discarded. 
The comparison was performed on the bases of fluxes (J) since the flux is the most relevant permeation 
parameter (EMA, 2014). Indeed, considering that both the J and the Cmax can be considered kinetic 
descriptors, the same statistically approach for assessing bioequivalence in vitro can be also applied for 
calculating the acceptance interval to assess the equivalence between the permeation fluxes of two products.  
The statistical analysis of the skin permeation experiments was upon a null hypothesis of non-equivalence 
considering the treatment of parallel experiments: 
 
Hypothesis testing: 
H0: MeanReference - Meantest < L;  Meanreference - Meantest > U 
H1: L < MeanReference - Meantest < U 
 
The choice for the parallel design has been done considering the asset of the experiment: two treatments 
assigned randomly at each experimental unit, constitute by Franz cells plus skin patch, exposed univocally 
and independently to each treatment.  
In general, the acceptability interval for the difference of the means in the log scale is 0.8-1.25 for 
bioequivalence study. However, in the case of data presenting a high variability, it could be computed using 
the total between-experimental unit variance. Thus, the U and L of the acceptability interval were therefore 
determined according to Eq. (2) and (3): 
                   (2) 
                    (3) 
where k is constant set to 0.760 (EMA, 2010) and σr is the standard deviation of the log-transformed values 
of J of the reference product. CV is the coefficient of variation of the log-transformed values of J of the 
reference product. For small estimates of σr
2, the σr can be approximated to CV (Julious, 2004).  
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Therefore, the Eq. (2) and (3) can be written as: 
                   (4) 
                    (5) 
 
For assessing the equivalence of the fluxes of two formulations in the logarithmic form the Two One-Sided 
Test Procedure (TOST; α = 0.05) was used in agreement with Schuirmann (Schuirmann, 1987). The SAS 9.4 
TS Level 1M3 (SAS Institute Inc., USA) procedure used was reported in the Supplementary materials. 
 
3 Results  
3.1 Propranolol 
The propranolol permeation profile and calculated fluxes are shown in Fig.1 and Table 1, respectively. The 
coefficient of variation of both the formulations resulted lower than 30% and therefore to assure the 
equivalence between the two patches the limits of the confidence intervals should be included in the 0.80-
1.25 as suggested by the EMA guideline on quality of transdermal patches (EMA, 2014). 
The application of the SAS procedure (see Supplementary materials for details) for calculating the interval 
of confidence assuming both the patches as a reference gave the following results:  
P-patch 1 vs P-patch 2: 0.8932 - 1.1843 
P-patch 2 vs P-patch 1: 0.8457 - 1.1210 
This data revealed that when the skin permeation variability is low, the equivalence between two drug 
products can be easily demonstrated using a limited number of replicas. 
 
3.2 Diclofenac epolamine 
The permeation fluxes of diclofenac through the epidermis of five different donors from the two plasters 
under evaluation are summarized in Table 2. As shown in Fig.2, the in vitro permeation profiles through the 
human epidermis of the reference and the test overlapped and the Geometric Mean Ratio (GMR) was close 
to 1 (GMR: 1.002). Nevertheless, as supposed on the basis of literature data, the fluxes showed a wide 
variability since the overall coefficient of variation resulted 55.50% and 47.31% for D-plaster 1 and D-
plaster 2, respectively. 
The average permeation profiles of diclofenac epolamine were represented in Fig.2.  
This high variability impeded the application of the 0.80-1.25 range (Zhang et al., 2013). However, 
considering that the flux (J) calculated in the in vitro permeation study is a kinetic descriptor as Cmax 
retrieved by the in vivo pharmacokinetic studies, the same methodological approach reported in the EMA 
guidance on the investigation of bioequivalence for assessing the bioequivalence of highly variable drugs or 
drug products (HVDP) could be applied (EMA, 2010). In accordance, the acceptance intervals determined 
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using Eq. (4) and (5) reported in Table 4 could be established. It should be underlined that according to the 
EMA guideline the maximum acceptable interval was 69.84 – 143.19% (CV% ≥ 50%) and, therefore, such 
range must be used for assessing equivalence D-plaster 1 vs D-plaster 2 instead of the calculated range 
(Table 3).  
The 90% confidence interval of the ratio between the experimentally determined J (Two One-Sided Test 
(TOST; α = 0.05) procedure calculated by SAS, see Supplementary materials) resulted: 
D-plaster 1 vs D-plaster 2: 0.7740 – 1.2982  
D-plaster 2 vs D-plaster 1: 0.7703– 1.2920 
Both the confidence intervals are included in the U, L limits reported in Table 4 confirming the equivalence 
of the two diclofenac epolamine plasters.  
 
3.3 Nitroglycerine 
The fluxes of N-patches per cm
2
 and normalized for the area of application of the patch are shown in Table 
4. As expected, the analysis of the equivalence performed by SAS procedure evidences that the two patches 
cannot be considered equivalent when the fluxes are calculated by the surface unit (g/cm2/h), whilst the 
confidence interval falls within the range indicated by the EMA guideline if the entire surface of the patch is 
considered (Table 5). 
 
4 Discussion 
The introduction of in vitro human skin permeation experiments in the EMA guideline (EMA, 2014) opens 
new opportunities in the development of transdermal patches and medicated plasters providing the possibility 
to rationalize the reduction of the number of in vivo studies. Nevertheless, the experimental set up has to be 
clearly designed and the critical variables validated (Ng et al., 2010) for their applicability to generic or 
abridged applications for drug products containing active pharmaceutical ingredients with a high skin 
permeation variability. This variability is determined not only by the physicochemical properties of the 
permeant (Franz et al., 2009), but also by the intrinsic physiological variability, which is related to a different 
composition of the stratum corneum lipids and/or keratins as well as their spatial organization (Gennari et al., 
2016). On the bases of these premises and the results obtained in the present experiment, the following 
remarks can be withdrawn. 
First, the validation of the method used to assess the skin sample integrity remains one of the main critical 
issues in the experimental set up of an in vitro skin permeation test. Even if the skin integrity control is a 
routine procedure which is usually performed before each permeation experiment, the available data is still 
limited and the values reported in the literature are not uniform (Table 6).  
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This could be related to different conditions or methods to isolate the biological membrane as well as the 
operative conditions to measure the skin integrity. The inter-laboratory comparability is still difficult and the 
obtained results in term of skin sample acceptability can be different. 
The defined operative conditions concerning the evaluation of skin integrity as well as Franz cell set up 
should be validated in the laboratory and monitored over time using molecules having different 
physicochemical characteristics and an in-house well-known permeation pattern (Musazzi, 2018).  
Secondly, the suitability of all operative conditions should be monitored over time using permeant with well-
known permeation patterns determined by intra-laboratory experiments. Indeed, the overall data revealed 
that the establishment of the number of replicas in in vitro skin permeation experiment is strictly dependent 
on the variability of the diffusion process which is obviously related to the physicochemical characteristics of 
the permeant. The caffeine and benzoic acid could be used (Musazzi, 2018), since it is expected that the 
former should permeate in a lower extent and with a higher variability (Van de Sandt et al., 2004). This 
dependence of the permeation pattern on the physicochemical properties of the permeant is well known by 
literature data. As mentioned before, for hydrophilic solutes like caffeine, in vitro skin permeation is much 
more sensitive to inter and/or intra-subject variation in skin barrier properties, compared to more lipophilic 
molecules like the parabens (Akomeah et al., 2007). 
Besides performing in vitro drug permeation studies, it is essential to consider the variability in the 
absorption of the tested permeant according to its physicochemical properties, mainly when these data are 
used to normalize/standardize or compare any generated data. The cases of propranolol and nicotine 
(permeants with a very low intra-individual variability) revealed that six or fewer replicas could be sufficient 
to demonstrate the equivalence between two patches and, therefore, in agreement with the EMA guideline a 
wider number of replicas are required merely to exclude a possible inter-donor variability. Conversely, in the 
case of diclofenac, a high number of replicas (n=20), which exceeds the number suggested by all the 
compendial guidelines [the OECD guideline reported at least four replicas per formulation (OECD, 2004), 
whereas the EMA guidelines on Transdermal Patch at least six replicas (EMA, 2014)] are needed. This large 
variability of the skin permeation profile of diclofenac epolamine, regardless of the vehicle used, was also 
reported in the literature (Minghetti et al., 2007) confirming the empirical relationship between the 
hydrophilicity and permeability of compounds. However, considering that the solubility of a compound in 
the stratum corneum environment changes as function of the pH of the human skin which is in turn 
influenced by the pH of the receiver medium (Wagner, 2003), the study of this parameter could be performed 
to reduce the variability of the permeation data. 
Thirdly, the analyses of the skin permeation data of medicated plaster or cutaneous patches (i.e., the 
formulation intended for a loco-regional administration) should be partially distinguished from those 
obtained by transdermal patches. Indeed, in the latter case, the total flux can be modulated by changing both 
the patch dimension and the drug content while in the former case the dimensions cannot be modified since 
they determine the area of the treatment. As a consequence, in the case of transdermal patches, fluxes should 
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be normalized for the effective patch area rather than the Franz cell permeation area. In this work, the results 
obtained with nitroglycerine confirm the ability of the designed experiments to discriminate different fluxes 
and meantime the in vitro-in vivo correlation in consideration that the two types of patches, qualitatively and 
quantitatively different but bioequivalent, gave the same fluxes per patches area. 
Fourth, in a regulatory perspective, the following aspects should be highlighted. The 90% confidence interval 
comprised within the ratio of 0.8 to 1.25 required by the EMA Guidelines to claim equivalence is an 
adequate range when the skin variability is low (i.e., CV lower than 25-30%). For permeants that exhibit a 
wider variability, the acceptable range could be extended using the Eq. (4) and (5) reported in this work. 
Accordingly, the number of replicas should be also increased. Nevertheless, the number of replicas cannot be 
easily predicted using the commonly used statistical approaches for parallel clinical studies since they are 
mainly based on the estimation of the intra-subject variability, which cannot be determined for in vitro skin 
permeation studies. As an example, when no difference between the flux means is hypothesized, the 
following equation can be applied (Julious, 2004): 
   
                    
 
   
          (6) 
where Z1-β/2 and Z1-α are the Z-values of Standard Normal Distribution calculated for Type I (α) and Type II 
error (β). In the case of  = 0.10 (Power: 90%) and  = 0.05, the Eq. (6) becomes: 
   
       
  
            (7) 
Even considering a low variability, i.e. a permeant with a CV = 25%, the number of replicas, calculated 
using Eq. (7), resulted in 34 replicas, which is six-fold higher than the number indicated by the EMA 
guideline and used in this work for propranolol patches. 
In conclusion, the skin penetration studies could be designed following the well-established approach 
defined for in vivo bioequivalence study. Nevertheless, the most significant output of the experiment, namely 
the flux of the permeant through the skin should be treated as the Cmax since it is obviously a kinetic 
parameter. Furthermore, in the case of a high variable permeant, the number of replicas should be established 
on the basis of the experience since, to the best of our knowledge, no suitable model to predict them is 
available. Further studies may permit to relate the CV with an acceptable range of replicas. 
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Figure captions  
 
Figure 1 In vitro propranolol skin permeation profiles obtained by propranolol patches (mean±Dv.st; n=6). 
Figure 2 Permeation profiles of D-plaster 1 and D-plaster 2 plasters (mean±Dv.st; n=20). 
 
Tables 
Table 1 – Permeation fluxes (J) of propranolol obtained by P-patch 1 and P-patch 2. 
Epidermis Donor 
J (g/cm2/h) 
P-patch 1 P-patch 2 
A 12.43±1.50 12.03±1.20 
B 10.93±1.51 10.67±1.59 
All 11.70±0.80 11.40±1.57 
 
Table 2 – Permeation fluxes (J) of Diclofenac obtained by D-plaster 1 and D-plaster 2. 
Epidermis Donor 
J (g/cm2/h) 
D-plaster 1 D-plaster 2 
C 0.240±0.049 0.207±0.129 
D 0.287±0.075 0.245±0.075 
E 0.145±0.051 0.178±0.048 
F 0.151±0.069 0.150±0.064 
G 0.198±0.118 0.214±0.069 
All 0.205±0.081 0.198±0.080 
 
Table 3 – Upper (U) and lower limits (L) of the acceptability interval calculated on the bases of overall J 
data of D-plaster 1 or D-plaster 2. 
Plaster Limits Calculated Value 
D-plaster 1 U 1.5247 
 L 0.6559 
D-plaster 2 U 1.4327 
 L 0.6980 
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Table 4 – Permeation fluxes of nitroglycerine obtained by the tested patches and calculated on the basis of 
the permeation (J) and application (Jtot) area, respectively. 
 
 
J  
(g/cm2/h) 
Jtot 
(g/patch area/h) 
N-patch 1 28.35±4.85 510.30±87.27  
N-patch 2 35.88±3.04  502.32±42.61 
 
Table 5 – Confidence intervals of the fluxes (J and Jtot) of the two commercial nitroglycerine patches 
 Confidence interval 
 (g/cm2/h)  (g/patch area/h) 
N-patch 1 vs N-patch 2 0.6448-0.9505 0.8291-1.2221 
N-patch 2 vs N-patch 1 1.0520-1.5508 0.8181-1.2062 
 
Table 6 – Intervals of electrical resistance (R) available in the literature for assessing the integrity of human 
skin membranes. 
Permeation membrane R acceptability interval Reference 
Human cadaver skin ≥ 15-20 kΩcm2 (Chantasart et al., 2013) 
Human cadaver skin ≥ 35 kΩcm2 (Kasting and Bowman, 1990) 
Human epidermis > 50 kΩcm2 (Mitragotri, 2000) 
Human full-thickness skin 12-120 kΩcm2 (Baroli et al., 2007) 
Human epidermis 20 kΩcm2 Current study 
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